SLC5A2 and chronic kidney disease: Given the significant improvement seen in CKD progression, SGLT2 inhibitors are now recommended for CKD with albuminuria regardless of the presence of diabetes, as it has been shown to slow estimated glomerular filtration rate (eGFR) decline, delay the onset of end stage kidney disease (ESKD), and decrease all-cause mortality (148).